Impact of New Systemic Therapies on Overall Survival of Patients with Metastatic Castration Resistant Prostate Cancer in a Hospital-based Registry

BACKGROUND: In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new systemic therapies have been shown to prolong OS in men with mCRPC. We sought to evaluate the aggregate impact of these newer...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Prostate Cancer Prostatic Dis
Main Authors: Francini, Edoardo, Gray, Kathryn P., Shaw, Grace K., Evan, Carolyn P., Hamid, Anis A., Perry, Caitlin E., Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Christopher J.
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7869825/
https://ncbi.nlm.nih.gov/pubmed/30643173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-018-0121-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker